Estrogens, Progestins, and Risk of Breast Cancer

  • M. C. Pike
  • A. H. Wu
  • D. V. Spicer
  • S. Lee
  • C. L. Pearce
Conference paper
Part of the Ernst Schering Foundation Symposium Proceedings book series (SCHERING FOUND, volume 2007/1)


Obesity is associated with a decreased risk of breast cancer in premenopausal women but an increased risk in postmenopausal women, an effect that increases with time since menopause. Analysis of these effects of obesity shows that there is a ceiling to the carcinogenic effect of estrogen on the breast; increases in nonsex hormone-binding globulin-bound estradiol (non-SHBG bound E2) exceeding approximately 10.2 pg/ml have no further effect on breast cancer risk; this ceiling is lower than the lowest level seen during the menstrual cycle. This suggests that the effects of menopausal estrogen therapy (ET) and menopausal estrogen–progestin therapy (EPT) on a woman's breast cancer risk will greatly depend on her body mass index (BMI; weight in kilograms/height in meters squared, kg/m2) with the largest effects being in slender women. Epidemiological studies confirm this prediction. Our best estimates, per 5 years of use, of the effects of ET on breast cancer risk is a 30% increase in a woman with a BMI of 20 kg/m2 decreasing to an 8% increase in a woman with a BMI of 30 kg/m2; the equivalent figures for EPT are 50% and 26%. The analysis of the effects of estrogen also shows that even reducing the dose of estrogen in ET and EPT by as much as a half will have little or no effect on these risks. Reducing the progestin dose is likely to significantly reduce the risk of EPT: this is possible with an endometrial route of administration.


Breast Cancer Breast Cancer Risk Estrogen Therapy Menopausal Hormone Therapy Conjugated Equine Estrogen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by a Department of Defense Congressionally Directed Breast Cancer Program Grant BC 044808; by the USC/Norris Comprehensive Cancer Center Core Grant P30 CA14089; and by generously donated funds from the endowment established by Flora L. Thornton for the Chair of Preventive Medicine at the USC/Norris Comprehensive Cancer Center. The funding sources had no role in this report.


  1. Anderson TJ, Ferguson DJ, Raab GM (1982) Cell turnover in the “resting” human breast: influence of parity, contraceptive pill, age and literality. Br J Cancer 46:376–382PubMedCrossRefGoogle Scholar
  2. Beral V, Reeves G, Banks E (2005) Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women. Br J Obstet Gynaecol 112:692–695CrossRefGoogle Scholar
  3. Cairns J (2002) Somatic stem cells and the kinetics of mutagenesis and carcinogenesis. Proc Natl Acad Sci USA 99:10567–10570PubMedCrossRefGoogle Scholar
  4. Chlebowski RT, Hendrix SL, Langer RD et al. (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289:3243–3253PubMedCrossRefGoogle Scholar
  5. Colditz GA, Rosner B (2000) Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 152:950–964PubMedCrossRefGoogle Scholar
  6. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059CrossRefGoogle Scholar
  7. Cook PJ, Doll R, Fellingham SA (1969) A mathematical model for the age distribution of cancer in man. Cancer 4:93–112Google Scholar
  8. Cutler SY, Young JL (1975) Third national cancer survey: incidence data. National Cancer Institute monograph No. 41. National Cancer Institute, Washington DCGoogle Scholar
  9. Dunn JF, Nisula BC, Rodbard D (1981) Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 53:58–68PubMedCrossRefGoogle Scholar
  10. Endogenous Hormones and Breast Cancer Collaborative Group (2003a) Free estradiol and breast cancer risk in postmenopausal women: comparison of measured and calculated values. Cancer Epidemiol Biomarkers Prev 12:1457–1461Google Scholar
  11. Endogenous Hormones and Breast Cancer Collaborative Group (2003b) Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95:1218–1226CrossRefGoogle Scholar
  12. Fournier A, Berrino F, Riboli E et al. (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448–454PubMedCrossRefGoogle Scholar
  13. Goebelsmann U, Mishell DR (1979) The menstrual cycle. In: Mishell DR, Davajan V (eds) Reproductive endocrinology, infertility and contraception. FA Davis, Philadelphia, pp 67–89Google Scholar
  14. Greendale GA, Reboussin BA, Slone S et al. (2003) Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 95:30–37PubMedCrossRefGoogle Scholar
  15. Hartz AJ, Barboriak TN, Wong A et al. (1979) The association of obesity with infertility and related menstrual abnormalities in women. Int J Obes 3:57–73PubMedGoogle Scholar
  16. Henderson BE, Ross RK, Judd HL et al. (1985) Do regular ovulatory cycles increase breast cancer risk? Cancer 56:1206–1208PubMedCrossRefGoogle Scholar
  17. Kelsey JL, Bernstein L (1996) Epidemiology and prevention of breast cancer. Annu Rev Public Health 17:47–67PubMedCrossRefGoogle Scholar
  18. Lee SA, Ross RK, Pike MC (2005) An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 92:2049–2058PubMedCrossRefGoogle Scholar
  19. MacMahon B, Cole P, Brown J (1973) Etiology of human breast cancer: a review. J Natl Cancer Inst 50:21–42PubMedGoogle Scholar
  20. Meyer JS, Connor RE (1982) Cell proliferation in fibrocystic disease and postmenopause breast ducts measured by thymidine labeling. Cancer 50:746–750PubMedCrossRefGoogle Scholar
  21. Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427CrossRefGoogle Scholar
  22. Nachtigall LE, Raju U, Banerjee S et al. (2000) Serum estradiol profiles in postmenopausal women undergoing three common estrogen replacement therapies: associations with sex hormone-binding globulin, estradiol, and estrone levels. Menopause 7:243–250PubMedCrossRefGoogle Scholar
  23. Pike MC, Krailo MD, Henderson BE et al. (1983) “Hormonal” risk factors, “breast tissue age” and the age-incidence of breast cancer. Nature 303:767–770PubMedCrossRefGoogle Scholar
  24. Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15:17–35PubMedGoogle Scholar
  25. Powers MS, Schennkel L, Darley PE et al. (1985) Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17-β estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 152:1099–1106PubMedGoogle Scholar
  26. Ropponen A, Aittomaki K, Vihma V et al. (2005) Effects of oral estradiol administration on levels of sex hormone-binding globulin in postmenopausal women with and without a history of intrahepatic cholestasis of pregnancy. J Clin Endocrinol Metab 90:3431–3434PubMedCrossRefGoogle Scholar
  27. Rosner B, Colditz GA, Willett WC (1994) Reproductive risk factors in a prospective study of breast cancer: The Nurses' Health Study. Am J Epidemiol 139:819–835PubMedGoogle Scholar
  28. Schairer C, Lubin J, Troisi R et al. (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485–491PubMedCrossRefGoogle Scholar
  29. Schiff I, Sela HK, Cramer D et al. (1982) Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril 37:79–82PubMedGoogle Scholar
  30. Selby PL, Peacock M (1986) Dose dependent response of symptoms, pituitary, and bone to transdermal estrogen in postmenopausal women. BMJ 293:1337–1339PubMedCrossRefGoogle Scholar
  31. Shoupe D, Meme D, Mezrow G, Lobo RA (1991) Prevention of endometrial hyperplasia in postmenopausal women with intrauterine progesterone. N Engl J Med 325:1811–1812PubMedCrossRefGoogle Scholar
  32. Södergard R, Backstrom T, Shanbhag V, Carstensen H (1982) Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 16:801–810PubMedCrossRefGoogle Scholar
  33. Stanczyk FZ (2002) Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord 3:211–224PubMedCrossRefGoogle Scholar
  34. Trichopoulos D, MacMahon B, Cole P (1972) Menopause and breast cancer risk. J Natl Cancer Inst 48:605–613PubMedGoogle Scholar
  35. Trichopoulos D, Hsieh CC, MacMahon B et al. (1983) Age at any birth and breast cancer risk. Int J Cancer 31:701–704PubMedCrossRefGoogle Scholar
  36. van den Brandt P, Spiegelman D, Yaun SS et al. (2000) Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152:514–527PubMedCrossRefGoogle Scholar
  37. Varila E, Wahlstrom T, Rauramo I (2001) A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 76:969–973PubMedCrossRefGoogle Scholar
  38. Wohlfahrt J, Melbye M (2001) Age at any birth is associated with breast cancer risk. Epidemiology 12:68–73PubMedCrossRefGoogle Scholar
  39. Women's Health Initiative (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291:1701–1712CrossRefGoogle Scholar
  40. Wood CE, Register TC, Lees CJ et al. (2007) Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 101:125–134PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • M. C. Pike
    • 1
  • A. H. Wu
    • 1
  • D. V. Spicer
    • 1
  • S. Lee
    • 1
  • C. L. Pearce
    • 1
  1. 1.Departments of Preventive Medicine and MedicineUniversity of Southern California/Norris Comprehensive Cancer CenterLos Angeles, CA 90033USA

Personalised recommendations